News

FDA calls for more safety data, patient counseling for Essure


 

References

Rep. Mike Fitzpatrick (R-Pa.), who has been critical of Essure, said that the FDA’s actions are inadequate and said he will push for congressional action, including blocking government agencies from purchasing the device and revoking the FDA’s approval of Essure.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Letrozole doesn’t cut multiple births compared to standard therapy
MDedge Endocrinology
Evidence links common endocrine-disrupting chemicals to obesity, diabetes, reproductive disorders
MDedge Endocrinology
Chronic insomnia afflicts one in three perimenopausal women
MDedge Endocrinology
Midlife contraception strategy should include transition to menopause
MDedge Endocrinology
What’s in the pipeline for female sexual problems?
MDedge Endocrinology
Denosumab better at building bone than zoledronic acid
MDedge Endocrinology
AES: Hormonal contraceptives can boost seizures in epileptics
MDedge Endocrinology
How new dietary guidelines affect health care providers
MDedge Endocrinology
Contraceptive ring, implant, and DMPA tied to lower sexual interest
MDedge Endocrinology
Review shows small benefit, significant safety concerns for flibanserin
MDedge Endocrinology

Related Articles